JP2014158485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014158485A5 JP2014158485A5 JP2014080445A JP2014080445A JP2014158485A5 JP 2014158485 A5 JP2014158485 A5 JP 2014158485A5 JP 2014080445 A JP2014080445 A JP 2014080445A JP 2014080445 A JP2014080445 A JP 2014080445A JP 2014158485 A5 JP2014158485 A5 JP 2014158485A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- erbb3
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 329
- 150000001413 amino acids Chemical class 0.000 claims 31
- 238000012217 deletion Methods 0.000 claims 12
- 230000037430 deletion Effects 0.000 claims 12
- 238000006467 substitution reaction Methods 0.000 claims 12
- 238000007792 addition Methods 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 230000006229 amino acid addition Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477089P | 2011-04-19 | 2011-04-19 | |
| US61/477,089 | 2011-04-19 | ||
| US201161539297P | 2011-09-26 | 2011-09-26 | |
| US61/539,297 | 2011-09-26 | ||
| US201161558192P | 2011-11-10 | 2011-11-10 | |
| US61/558,192 | 2011-11-10 | ||
| US201261619244P | 2012-04-02 | 2012-04-02 | |
| US61/619,244 | 2012-04-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506549A Division JP5588086B2 (ja) | 2011-04-19 | 2012-04-19 | 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014158485A JP2014158485A (ja) | 2014-09-04 |
| JP2014158485A5 true JP2014158485A5 (OSRAM) | 2015-06-11 |
| JP6214453B2 JP6214453B2 (ja) | 2017-10-18 |
Family
ID=47021510
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506549A Expired - Fee Related JP5588086B2 (ja) | 2011-04-19 | 2012-04-19 | 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体 |
| JP2014080445A Expired - Fee Related JP6214453B2 (ja) | 2011-04-19 | 2014-04-09 | 単一特異性および二重特異性抗ｉｇｆ‐１ｒ抗体および抗ｅｒｂｂ３抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506549A Expired - Fee Related JP5588086B2 (ja) | 2011-04-19 | 2012-04-19 | 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8476409B2 (OSRAM) |
| EP (2) | EP2699602B1 (OSRAM) |
| JP (2) | JP5588086B2 (OSRAM) |
| KR (2) | KR101517320B1 (OSRAM) |
| CN (2) | CN105884900A (OSRAM) |
| AU (2) | AU2012245491C1 (OSRAM) |
| BR (1) | BR112013027021A2 (OSRAM) |
| CA (1) | CA2833643A1 (OSRAM) |
| DK (1) | DK2699602T3 (OSRAM) |
| ES (1) | ES2625818T3 (OSRAM) |
| HK (1) | HK1223383A1 (OSRAM) |
| HR (1) | HRP20170713T1 (OSRAM) |
| HU (1) | HUE034276T2 (OSRAM) |
| IL (1) | IL228957A0 (OSRAM) |
| MX (2) | MX336197B (OSRAM) |
| PL (1) | PL2699602T3 (OSRAM) |
| PT (1) | PT2699602T (OSRAM) |
| SI (1) | SI2699602T1 (OSRAM) |
| TW (1) | TWI631136B (OSRAM) |
| WO (1) | WO2012145507A2 (OSRAM) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| CA2777242A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| JP2013522237A (ja) | 2010-03-11 | 2013-06-13 | メリマック ファーマシューティカルズ インコーポレーティッド | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
| HRP20170713T1 (hr) * | 2011-04-19 | 2017-07-14 | Merrimack Pharmaceuticals, Inc. | Bispecifično anti-igf-1r i anti-erbb3 antitijelo |
| JP2015514113A (ja) * | 2012-04-02 | 2015-05-18 | メリマック ファーマシューティカルズ インコーポレーティッド | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| CN104341504B (zh) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2015130554A2 (en) * | 2014-02-20 | 2015-09-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
| JP6835591B2 (ja) * | 2014-04-25 | 2021-02-24 | ピエール、ファーブル、メディカマン | Ｉｇｆ−１ｒ抗体および癌処置のためのアドレッシングビヒクルとしてのその使用 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| AU2016271138A1 (en) * | 2015-05-29 | 2017-12-07 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| HK1257216A1 (zh) | 2015-08-20 | 2019-10-18 | 益普生生物制药有限公司 | 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法 |
| BR112018002941B1 (pt) | 2015-08-21 | 2023-12-05 | Ipsen Biopharm Ltd | Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas |
| BR112018006922B1 (pt) | 2015-10-16 | 2023-11-21 | Ipsen Biopharm Ltd | Composições de irinotecano lipossômico estabilizado para armazenamento |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| US20170233491A1 (en) | 2016-01-19 | 2017-08-17 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment |
| CN109310755A (zh) * | 2016-02-02 | 2019-02-05 | 卡德门企业有限公司 | Pd-l1和kdr的双特异性结合蛋白 |
| US10723857B1 (en) * | 2016-04-15 | 2020-07-28 | United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration | Polyimide aerogels with reduced shrinkage from isothermal aging |
| WO2018045256A1 (en) * | 2016-09-02 | 2018-03-08 | Merrimack Pharmaceuticals, Inc. | Combination of an erbb3 inhibitor, topoisomerase i inhibitor, and an alkylating agent to treat cancer |
| JP6825284B2 (ja) * | 2016-09-21 | 2021-02-03 | カシオ計算機株式会社 | イメージ作成装置、イメージ作成方法、及び、プログラム |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| DK3628049T3 (da) * | 2017-05-04 | 2023-08-14 | Acceleron Pharma Inc | Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf |
| CN107602702A (zh) * | 2017-09-22 | 2018-01-19 | 生标（上海）医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| US10640576B2 (en) | 2018-04-10 | 2020-05-05 | Y-Biologics Inc. | Cell engaging binding molecules |
| CN112888445B (zh) | 2018-08-30 | 2025-06-10 | 免疫生物公司 | 治疗老年化相关病症的方法 |
| CN120535649A (zh) | 2018-08-30 | 2025-08-26 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| NZ772550A (en) | 2018-08-30 | 2025-08-29 | Immunitybio Inc | Multi-chain chimeric polypeptides and uses thereof |
| KR20220035394A (ko) | 2019-06-21 | 2022-03-22 | 에이치씨더블유 바이올로직스, 인크. | 다중-사슬 키메라 폴리펩티드 및 이의 용도 |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| CN113512116B (zh) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| KR20230031280A (ko) | 2020-06-01 | 2023-03-07 | 에이치씨더블유 바이올로직스, 인크. | 노화 관련 장애의 치료 방법 |
| CN118043351A (zh) * | 2021-08-31 | 2024-05-14 | 上海医药集团股份有限公司 | 靶向Siglec15的抗原结合蛋白及其用途 |
| JP2025508939A (ja) | 2022-03-02 | 2025-04-10 | イミュニティーバイオ インコーポレイテッド | 膵臓癌の治療方法 |
| CN120623322B (zh) * | 2025-08-14 | 2025-12-05 | 成都蓉生药业有限责任公司 | 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| PT896586E (pt) | 1996-03-27 | 2007-01-31 | Genentech Inc | Anticorpos de erbb3 |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| AU2001294175A1 (en) | 2000-10-06 | 2002-04-22 | Kyowa Hakko Kogyo Co. Ltd. | Method of purifying antibody |
| AR032028A1 (es) * | 2001-01-05 | 2003-10-22 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| JP2005500018A (ja) | 2001-04-02 | 2005-01-06 | アイデック ファーマスーティカルズ コーポレイション | ＧｎＴＩＩＩと同時発現する組換え抗体 |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7638605B2 (en) * | 2003-05-01 | 2009-12-29 | ImClone, LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| MX2007013924A (es) | 2005-05-09 | 2008-01-28 | Glycart Biotechnology Ag | Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc. |
| US7951918B2 (en) * | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| WO2008140493A2 (en) * | 2006-11-21 | 2008-11-20 | The Regents Of The University Of Californina | Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof |
| HRP20131113T1 (hr) * | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| US20100166747A1 (en) * | 2007-03-02 | 2010-07-01 | Beltran Pedro J | Methods and compositions for treating tumor diseases |
| CN101842116A (zh) * | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | 结合igf-1r多个表位的组合物 |
| MX2010011145A (es) | 2008-04-11 | 2011-04-11 | Merrimack Pharmaceuticals Inc | Enlazadores de la albumina de suero humana y conjugados de la misma. |
| BRPI0917871A2 (pt) | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
| US8362215B2 (en) | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
| RU2570633C2 (ru) * | 2009-05-27 | 2015-12-10 | Ф.Хоффманн-Ля Рош Аг | Три- или тетраспецифические антитела |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2467164A2 (en) | 2009-08-21 | 2012-06-27 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of erbb3 and uses thereof |
| TW201119673A (en) | 2009-09-01 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CA2777242A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| DK2516469T3 (en) | 2009-12-22 | 2016-05-02 | Roche Glycart Ag | ANTI-HER3 antibodies and uses thereof |
| WO2011136911A2 (en) | 2010-04-09 | 2011-11-03 | Aveo Pharmaceuticals, Inc. | Anti-erbb3 antibodies |
| PL2606070T3 (pl) * | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) |
| HRP20170713T1 (hr) | 2011-04-19 | 2017-07-14 | Merrimack Pharmaceuticals, Inc. | Bispecifično anti-igf-1r i anti-erbb3 antitijelo |
| JP2015514113A (ja) * | 2012-04-02 | 2015-05-18 | メリマック ファーマシューティカルズ インコーポレーティッド | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 |
| WO2015130554A2 (en) * | 2014-02-20 | 2015-09-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
| US20170233491A1 (en) * | 2016-01-19 | 2017-08-17 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment |
-
2012
- 2012-04-19 HR HRP20170713TT patent/HRP20170713T1/hr unknown
- 2012-04-19 BR BR112013027021A patent/BR112013027021A2/pt not_active Application Discontinuation
- 2012-04-19 DK DK12773950.6T patent/DK2699602T3/en active
- 2012-04-19 KR KR1020137030562A patent/KR101517320B1/ko not_active Expired - Fee Related
- 2012-04-19 HU HUE12773950A patent/HUE034276T2/en unknown
- 2012-04-19 MX MX2013012201A patent/MX336197B/es unknown
- 2012-04-19 ES ES12773950.6T patent/ES2625818T3/es active Active
- 2012-04-19 CN CN201510472421.9A patent/CN105884900A/zh active Pending
- 2012-04-19 JP JP2014506549A patent/JP5588086B2/ja not_active Expired - Fee Related
- 2012-04-19 CA CA2833643A patent/CA2833643A1/en not_active Abandoned
- 2012-04-19 US US13/451,135 patent/US8476409B2/en active Active
- 2012-04-19 KR KR1020147031817A patent/KR20140138353A/ko not_active Ceased
- 2012-04-19 PT PT127739506T patent/PT2699602T/pt unknown
- 2012-04-19 EP EP12773950.6A patent/EP2699602B1/en active Active
- 2012-04-19 WO PCT/US2012/034244 patent/WO2012145507A2/en not_active Ceased
- 2012-04-19 MX MX2016000234A patent/MX346486B/es unknown
- 2012-04-19 PL PL12773950T patent/PL2699602T3/pl unknown
- 2012-04-19 SI SI201230955A patent/SI2699602T1/sl unknown
- 2012-04-19 TW TW101114063A patent/TWI631136B/zh not_active IP Right Cessation
- 2012-04-19 EP EP17158234.9A patent/EP3214096A3/en not_active Withdrawn
- 2012-04-19 AU AU2012245491A patent/AU2012245491C1/en not_active Ceased
- 2012-04-19 CN CN201280028639.XA patent/CN103703026B/zh not_active Expired - Fee Related
-
2013
- 2013-02-27 US US13/778,984 patent/US9556274B2/en not_active Expired - Fee Related
- 2013-10-17 IL IL228957A patent/IL228957A0/en unknown
-
2014
- 2014-04-09 JP JP2014080445A patent/JP6214453B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-17 US US14/857,344 patent/US9527914B2/en not_active Expired - Fee Related
-
2016
- 2016-08-26 US US15/248,562 patent/US9938346B2/en active Active
- 2016-10-10 HK HK16111680.4A patent/HK1223383A1/zh unknown
-
2017
- 2017-08-16 AU AU2017216490A patent/AU2017216490A1/en not_active Abandoned